Screened 2026-08-26 · the tape above runs as of 08:38 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its accumulation label.
MiniMed Group, Inc. holds its Accumulation at $19.49.
As held on the ledger · 2026-08-26
Phase
Accumulation
Price at the screen
$19.49
Valuation
N/A trailing · 29.75 forward price to earnings
Values screen
PASS· score 70.0
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
3.13%
Below 33%
Interest-bearing debt is just 3.1% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
10.76%
Below 49%
Money owed to the company is 10.8% of assets, under the 49% limit.
Pass
Revenue purity
0.00%
Below 5%
Only 0.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
Fair value range in USD, drawn from the 2026-08-26 screen. The gold marker is the market price at the same screen. The price runs 15.6% above the base estimate.
Third-party analyst targets: 12 covering, consensus Strong Buy. The average target sits +5% from the screen price.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-08-26 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Diabetes kit maker priced above its worth
Picture a patient relying on an insulin pump to stay steady through the day. The hardware matters, yet MiniMed runs at an 11% loss and negative return on equity while growing revenue 16%. At 25.6 times forward earnings on a business still losing money, the shares sit 4% above our fair value with no margin of safety left.
We pass. Analyst targets sit higher, yet the numbers show no durable edge and an unknown competitive moat. Ethical checks clear, but that alone does not turn losses into cash returns for owners.
Execution risk stays real in a crowded medtech field where reimbursement changes or new rivals can quickly widen the losses. The current price already bakes in optimism the balance sheet does not support.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
MMED trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-09-01Accumulation$19.49+0.0%Entry 12
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. The street (12 analysts) rates it strong buy, with a mean price target of $22. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-31Accumulation$19.49+0.0%Entry 11
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. The street (12 analysts) rates it strong buy, with a mean price target of $22. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-30Accumulation$19.49+0.0%Entry 10
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. The street (12 analysts) rates it strong buy, with a mean price target of $22. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-29Accumulation$19.49+0.0%Entry 9
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. The street (12 analysts) rates it strong buy, with a mean price target of $22. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-28Accumulation$19.49+0.0%Entry 8
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. The street (12 analysts) rates it strong buy, with a mean price target of $22. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-27Accumulation$19.49-0.6%Entry 7
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.6% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. The street (12 analysts) rates it strong buy, with a mean price target of $22. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-26Accumulation$19.60+0.0%Entry 6
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. The street (12 analysts) rates it strong buy, with a mean price target of $22. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 15.8% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. The street (12 analysts) rates it strong buy, with a mean price target of $22. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-05Markup · changed$16.93+11.7%Entry 4
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 11.7% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading neutral. The street (12 analysts) rates it strong buy, with a mean price target of $22.
2026-07-18Distribution$15.16+0.0%Entry 3
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading neutral. The street (12 analysts) rates it strong buy, with a mean price target of $22.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.